Advertisement

Related Videos

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Opportunities to Optimize Cancer Policies Panel Discussion

Opening Session Panel Discussion

Deborah Collyar: What's In It for Patients?

Advertisement

Advertisement




Jul
10
Today In Oncology
FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer
Long-Term Follow-up of Postoperative Chemoradiotherapy With 3-Weekly vs Weekly Cisplatin in Head and Neck Cancer
Novel Gene Fusion Detector for Pediatric B-ALL Shows High Sensitivity
Advanced Gastric or GEJ Cancer First-Line Disitamab Vedotin, Tislelizumab, and S-1
In the United States, Men May Be More Likely Than Women to Receive Later-Stage Diagnoses for Many Cancer Types
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo